Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor ile-thiazolidide

Metabolism: Clinical and Experimental

Volumn 48, Issue 3, 1999, Pages 385-389

  Pauly, Robert P ^b   Demuth, Hans Ulrich ^b   Rosche, Fred ^b   Schmidt, Jörn ^b   White, Heather A ^b   Lynn, Francis ^b   McIntosh, Christopher H S ^b   Pederson, Raymond A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; THIAZOLIDIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

EID: 0032969356     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90090-2     Document Type: Article

References (22)

1. Unger RH, Eisentraut AM: Entero-insular axis. Arch Intern Med 123:261-266, 1969
2. Fehmann H-C, Göke R, Göke B: Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 16:390-410, 1995
3. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1(7-36), peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
4. Kieffer TJ, McIntosh CHS, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
5. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocinol Metab 80:952-957, 1995
6. Pauly RP, Rosche F, Wermann M, et al: Investigation of glucose-dependent insulinotropic polypeptide (1-42) and glucagon-like peptide-1 (7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization time of flight mass spectrometry. J Biol Chem 271:23222-23229, 1996
7. Brown JC, Dahl M, McIntosh CHS, et al: Actions of GIP. Peptides 2:241-245, 1981
8. Suzuki S, Kawai K, Ohashi S, et al: Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology 125:3109-3114, 1989
9. Demuth H-U, Heins J: Catalytic mechanism of dipeptidyl peptidase IV, in Fleischer B (ed): Dipeptidyl Peptidase IV (CD26) in Fleischer B (ed): Metabolism and the Immune Response. Washington, DC, Landes Biochemical, Georgetown, 1995, pp 1-37
10. Schön E, Born I, Demuth H-U, et al: Dipeptidyl peptidase IV in the immune system. Biol Chem Hoppe Seyler 372:305-311, 1991
11. Demuth H-U: Recent developments in the irreversible inhibition of serine and cysteine proteases. J Enzym Inhib 3:249-278, 1990
12. Pederson RA, Buchan AMJ, Zahedi-Asl S, et al: Effect of jejunal bypass in the rat on the enteroinsular axis. Regul Pept 3:53-63, 1982
13. Gutniak MK, Larsson H, Heiber SJ, et al: Potential therapeutic levels of glucagon-like peptide 1 achieved in humans by a buccal tablet. Diabetes Care 19:843-848, 1996
14. Ørskov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptide-1 (proglucagon 78-107 amide) on endocrine secretion from the pig pancreas, antrum and stomach. Endocrinology 123:2009-2013, 1988
15. Creutzfeldt W, Kleine N, Willms B, et al: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1(7-36) amide in type 1 diabetic patients. Diabetes Care 19:580-586, 1996
16. D'Alessio DA, Kahn SE, Leusner CR, et al: Glucagon-like peptide enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266, 1994
17. D'Alessio DA, Prigeon RL, Ensinck JW: Enterai enhancement of glucose disposition by both insulin-dependent and insulin-independent processes: A physiological role of glucagon-like peptide 1. Diabetes 44:1433-1437, 1995
18. D'Alessio DA, Vogel R, Prigeon R, et al: Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:133-138, 1996
19. Deacon CF, Hughes TE, Hoist JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anaesthetized pig. Diabetes 47:764-769, 1998
20. Amiel SA: Glucagon-like peptide: A therapeutic glimmer. Lancet 343:4-5, 1994
21. Nathan DM, Schreiber E, Fogel H, et al: Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
22. Nauck MA, Holst JJ, Willms B: Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 29:411-416, 1997